# Autolus Therapeutics (stock symbol: AUTL) Logo in transparent PNG and SVG formats

## Autolus Therapeutics Logo large

### Autolus Therapeutics Logo large Download PNG (28.34 KB)

![Autolus Therapeutics Logo large Download PNG (28.34 KB)](/img/orig/AUTL_BIG-a155092b.png)

### Autolus Therapeutics Logo large Download SVG (2.81 KB)

![Autolus Therapeutics Logo large Download SVG (2.81 KB)](/img/orig/AUTL_BIG-919f3d2d.svg)

## Autolus Therapeutics Logo icon format

### Autolus Therapeutics Logo icon format Download PNG (34.25 KB)

![Autolus Therapeutics Logo icon format Download PNG (34.25 KB)](/img/orig/AUTL-9cabc071.png)

### Autolus Therapeutics Logo icon format Download SVG (1.98 KB)

![Autolus Therapeutics Logo icon format Download SVG (1.98 KB)](/img/orig/AUTL-6b2db396.svg)

## Autolus Therapeutics Logo large for dark backgrounds

### Autolus Therapeutics Logo large for dark backgrounds Download PNG (28.71 KB)

![Autolus Therapeutics Logo large for dark backgrounds Download PNG (28.71 KB)](/img/orig/AUTL_BIG.D-08a38f32.png)

### Autolus Therapeutics Logo large for dark backgrounds Download SVG (2.81 KB)

![Autolus Therapeutics Logo large for dark backgrounds Download SVG (2.81 KB)](/img/orig/AUTL_BIG.D-7c955d84.svg)

## Autolus Therapeutics Logo icon format for dark backgrounds

### Autolus Therapeutics Logo icon format for dark backgrounds Download PNG (33.89 KB)

![Autolus Therapeutics Logo icon format for dark backgrounds Download PNG (33.89 KB)](/img/orig/AUTL.D-a6d33fce.png)

### Autolus Therapeutics Logo icon format for dark backgrounds Download SVG (1.98 KB)

![Autolus Therapeutics Logo icon format for dark backgrounds Download SVG (1.98 KB)](/img/orig/AUTL.D-82833e6f.svg)

## About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

1. Website domain: autolus.com
2. Employees: 324
3. Marketcap: $0.31 Billion USD


## Categories
- [x] ðŸ‡¬ðŸ‡§ United Kingdom
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
